XORTX Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XRTX.V research report →
Companywww.xortx.com
XORTX Therapeutics Inc. , a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy.
- CEO
- Allen Warren Davidoff
- IPO
- 2021
- Employees
- 2
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $985.85K
- P/E
- -1.30
- P/S
- 0.00
- P/B
- 2.79
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -135.33%
- ROIC
- -238.89%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,702,803 · 40.46%
- EPS
- $-14.20 · 64.05%
- Op Income
- $-3,313,012
- FCF YoY
- 44.10%
Performance & Tape
- 52W High
- $9.85
- 52W Low
- $1.29
- 50D MA
- $3.27
- 200D MA
- $4.20
- Beta
- 0.29
- Avg Volume
- 1.70K
Get TickerSpark's AI analysis on XRTX.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our XRTX.V Coverage
We haven't published any research on XRTX.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XRTX.V Report →